Inhaltspezifische Aktionen

Selected Publications

  1. Hussain, A. F., Grimm, A., Sheng, W., Zhang, C., Al-Rawe, M., Bräutigam, K., Abu Mraheil, M., Zeppernick, F., Meinholld-Heerlein, I. Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches (2021). Pharmaceuticals. doi: 10.3390/ph14040343.
  2. Bräutigam, K., Kabore-Wolff, E., Hussain, A. F., Polack, S., Rody, A., Hanker, L., Köster, F. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines (2021). Journal of Cancer Research and Clinical Oncology. doi: 10.1007/s00432-021-03694-4.
  3. Hussain, A. F., Heppenstall, P. A., Kampmeier, F., Meinhold-Heerlein, I., Barth, S. One-step site-specific antibody fragment conjugation using SNAP-tag technology. Nature Protocols (2019). doi: 10.1038/s41596-019-0214-y.
  4. Maennling, A. M., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F., Gattenlöhner, S., Meinhold-Heerlein, I., Hussain, A. H. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (2019). doi: 10.3390/cancers11121826.
  5. Nachreiner, I.,* Hussain, A. F.,* Wullner, U., Machuy, N., Meyer, T. T., Fischer, R., Gattenlöhner, S., Meinhold-Heerlein, I., Barth, S., Tur, M. K. Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras. Accepted for publication in Experimental and Therapeutic Medicine (2019). doi: 10.3892/etm.2019.7753.
  6. Wollschlaeger, C., Meinhold-Heerlein, I., Cong, X., Bräutigam, K., Di Fiore, S., Zeppernick, F., Klockenbring, T., Stickeler, E., Barth, S. and Hussain, A. F. Simultaneous and Independent Dual Site-Specific Self-Labeling of Recombinant Antibodies. Bioconjugate Chemistry (2018). doi: 10.1021/acs.bioconjchem.8b00545.
  7. Dhandapani, R., Arokiaraj, C., Taberner, F., Pacifico, P., Raja, S., Nocchi, L., Portulano, C., Franciosa, F., Maffei, M., Hussain, A. F., de Castro Reis, F., Reymond, L., Perlas, E., Garcovich, S., Barth, S., Johnsson, K., Lechner, S. and Heppenstall. P., Control of mechanical pain hypersensitivity through ligand-targeted photoablation of TrkB positive sensory neurons. Nature Communications (2018). doi: 10.1038/s41467-018-04049-3.
  8. Bauerschlag, D., Meinhold-Heerlein, I., Maass, N., Bleilevens, A., Bräutigam, K., Al Rawashdeh, W., Di Fiore, S., Haugg, A. M., Gremse, F., Steitz, J., Fischer, R., Stickeler, E., Barth, S. and Hussain, A. F. Detection and specific elimination of EGFR+ ovarian cancer cells using near infrared photoimmunotheranostics approach. Pharmaceutical Research (2017). doi: 10.1007/s11095-017-2096-4.
  9. Chouman, K., Woitok, M., Kessler, C., Mladenov, R., Weinhold, E., Hanz, G., Fischer, R., Meinhold-Heerlein, I., Bleilevens, A., Haugg, A. M., Stickeler, E., Kolberg, K. and Hussain, A. F. Fine tuning antibody conjugation methods using snap tag technology, Anti-Cancer Agents in Medicinal Chemistry (2017). doi: 10.2174/1871520617666170213123737.
  10. Amoury, M., Bauerschlag, D., Zeppernick, F., von Felbert, V., Berges, N., Di Fiore, S., Mintert, I., Bleilevens, B., Maass, N., Bräutigam, K., Meinhold-Heerlein, I., Stickeler, E., Barth, S., Fischer, R. and Hussain, A. F. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand, Oncotarget (2016).
  11. Amoury, M., Kolberg, K., Pham, A. T., Hristodorov, D., Mladenov, R., Di Fiore, A. T., Helfrich, W., Kiessling, F., Fischer, R., Pardo, A., Thepen, T., Hussain, A. F., Nachreiner, T. and Barth, S. Granzyme b-based cytolytic fusion protein targeting Epcam specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model, Cancer Lett (2016). doi: 10.18632/oncotarget.10705.
  12. Von Felbert, V., Bauerschlag, D., Maass, N., Brautigam, K., Meinhold-Heerlein, I., Woitok, M., Barth, S. and Hussain A. F. A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR, J Cancer Res Clin Oncol (2016). doi: 10.1007/s00432-016-2122-7.
  13. Amoury, M., Mladenov, R., Nachreiner, T., Pham, A. T., Hristodorov, D., Di Fiore, S., Helfrich, W., Pardo, A., Fey, G., Schwenkert, M., Thepen, T., Kiessling, F., Hussain, A. F., Fischer, R., Kolberg, K. and Barth, S. A novel approach for targeted elimination of cspg4-positive triple-negative breast cancer cells using a map tau-based fusion protein, Int J Cancer (2016). doi: 10.1002/ijc.30119.
  14. Hussain, A. F., Krüger, H.R., Kampmeier, F., Weissbach, T., Licha, K., Kratz, F., Haag, R., Calderón, M., Barth, S. Targeted delivery of dendritic polyglycerol-doxorubicin conjugates by scFv-SNAP fusion protein suppresses EGFR+ cancer cell growth. Biomacromolecules (2013). doi: 10.1021/bm400410e.
  15. Hussain, A. F., Tur, M. T and Barth, S. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in αvβ3 integrin expressing cancers. Nucleic Acid Therapeutics (2013). doi: 10.1089/nat.2012.0408.
  16. Hussain, A. F., Amoury, M. and Barth, S. SNAP-tag technology: a powerful tool for site specific conjugation of therapeutic and imaging agents. Current Pharmaceutical Design (2013). DOI:10.2174/1381612811319300014
  17. Hussain, A. F., Wullner, U., Neef, I., Tur, M.K. and Barth, S. Targeted delivery of short interfering RNAs - strategies for in vivo delivery. Book chapter in Topics in anti-cancer research book. (2012). DOI: 10.2174/9781608054787112010011.
  18. Hussain, A. F., Kampmeier, F., von Felbert, V., Merk, H., Tur, M. T and Barth, S. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug. Chem. (2011). doi: 10.1021/bc200304k.